

## Simris Group CEO, Julian Read, answers questions from Finwire regarding company strategy and its ongoing Rights Issue

**Julian Read, CEO for Simris Group AB clarifies the strategic focus for the Company, its business model for its Antibody Drug Conjugate (ADC) products and how funds from the ongoing capital raising will be prioritised during an interview with Finwire.**

The interview can be viewed at [www.youtube.com/watch?v=ogonDAE4UuY&t=12s](https://www.youtube.com/watch?v=ogonDAE4UuY&t=12s).

### Contact Details:

Julian Read  
CEO Simris Group AB  
Email: [ir@simris.com](mailto:ir@simris.com)  
Mobile: +46767888212  
[www.simrisgroup.com](http://www.simrisgroup.com)

### About Simris Group AB (PUBL):

Simris Group is a biologics company identifying high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in skincare, nutrition, and biopharmaceuticals. The company sustainably grows microalgae and cyanobacteria at industrial scale within its photobioreactor facility whereby conditions are optimized for production of these high-value compounds.

Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: [info@amudova.se](mailto:info@amudova.se).

### Attachments

[Simris Group CEO, Julian Read, answers questions from Finwire regarding company strategy and its ongoing Rights Issue](#)